Upacit XR 15 mg | Generic Upadacitinib by Delta Pharma

Description

Dr. Daria KwaśniewskaESMO Certified Consultant Medical Oncologist

Reviewed June 2026

⚠ Prescription required. For informational purposes only. Meds For Cancer is a Named Patient Program facilitator — not a retail pharmacy.

Is Upacit XR 15 mg right for your situation?

Review these criteria with your doctor before enquiring

✔ You may be a candidate if

✓Moderate-to-severe active rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis with inadequate response to a TNF blocker
✓Moderate-to-severe atopic dermatitis in adults or adolescents 12+ uncontrolled by topical therapy
✓Moderate-to-severe active ulcerative colitis or Crohn’s disease
✓Need a generic alternative to Rinvoq® made by Delta Pharma

✖ May NOT be suitable if

✗Active serious infection — TB screening mandatory before starting
✗History of venous thromboembolism or major cardiovascular events
✗Pregnant or planning pregnancy
✗Age 65+ with cardiovascular risk factors

Check Availability & Pricing

Prescription required · Named Patient Program · Worldwide shipping

💬 WhatsApp: +880 130 449 8958 ✉ Email: info@medsforcancer.com

🛡 WHO-GMP Certified · Prescription verified · Express dispatch

What is Upacit XR 15 mg?

Upacit XR 15 mg is a generic extended-release formulation of Upadacitinib — a selective JAK-1 inhibitor — manufactured by Delta Pharma Ltd. under WHO-GMP certified conditions in Bangladesh. Each tablet contains 15 mg of upadacitinib, identical in active content to Rinvoq® (AbbVie), and is dispensed under the Named Patient Program.

Delta Pharma has built its DMARD portfolio over two decades — starting with Methotrax in 2004, followed by Reumaflex, Tofacit, and Baricit — with Upacit XR as its newest and most advanced JAK-inhibitor addition. Upadacitinib is a small molecule generic — not a biosimilar — taken orally once daily.

Generic name	Upadacitinib
Reference brand	Rinvoq® (AbbVie)
Manufacturer	Delta Pharma Ltd.
Standard	WHO-GMP Certified
Drug class	JAK-1 Selective Inhibitor
Dosage form	Extended-release tablet — 15 mg
Pack size	10 tablets per strip
Route	Oral · once daily, with or without food
Prescription	Required — physician only

How Upadacitinib Works

In autoimmune conditions, an overactive JAK signalling pathway drives chronic inflammation, causing joint damage, skin inflammation, and systemic symptoms.

Upadacitinib selectively inhibits JAK-1, reducing inflammatory cytokine production with greater selectivity than older, non-selective JAK inhibitors. In the SELECT-COMPARE trial it demonstrated superior ACR50 response versus adalimumab (Humira) in rheumatoid arthritis. It is included in ACR and international dermatology/GI society guidelines as a recommended advanced therapy across its approved indications.

What to Expect: First 30 Days

Upadacitinib typically shows faster onset than biologics — many patients notice improvement within 2–4 weeks.

Before starting: TB screening, blood counts, liver function, and lipid panel are required.
Weeks 1–2: Early reduction in joint pain, stiffness, and skin symptoms is common.
Weeks 3–4: Blood counts and lipids are rechecked. Full response assessed at 12 weeks.

Side Effects

Common · Usually Manageable

Upper respiratory infections
Nausea / headache
Acne / folliculitis
Elevated LDL cholesterol
Herpes zoster reactivation

Serious · Report Immediately

Serious or opportunistic infections
Venous thromboembolism (DVT/PE)
Major cardiovascular events
Malignancy
Gastrointestinal perforation

⚠ Call your doctor immediately for:

Fever or signs of serious infection
Leg swelling/pain, chest pain, breathlessness
Severe abdominal pain

How to Take Upacit XR 15 mg

Standard dose: 15 mg once daily for most indications · higher inductions (30–45 mg) may apply for atopic dermatitis, ulcerative colitis, or Crohn’s disease per your physician’s plan. With or without food. Do not crush or chew — this destroys the extended-release mechanism.

1
Once daily, same time each day — with or without food.
2
Swallow whole with water. Never crush, split, or chew.
3
Confirm TB screening is done before starting.
4
If you miss a dose, take it the same day. Skip if nearly time for next dose.

Frequently Asked Questions

Is Upacit XR a biosimilar?

No — it is a generic small-molecule drug. Upadacitinib is a chemically synthesised small molecule, not a biological protein. Delta Pharma’s generic version contains exactly the same active chemical compound as Rinvoq, produced to WHO-GMP quality standards.

What is the difference between Upacit XR and other upadacitinib brands on this site?

All upadacitinib brands stocked here (Upacit XR by Delta Pharma, Reucent XR by Incepta, Uparen by Renata, Upanib by Ziska, Rematib by Drug International) contain the same 15 mg extended-release upadacitinib active ingredient. The only differences are manufacturer and pack size. Contact us to confirm which brand is currently in stock for your country.

Why is TB screening mandatory?

JAK inhibitors including upadacitinib can cause latent TB to reactivate. A tuberculin skin test or IGRA blood test must confirm negative status (or latent TB must be treated) before starting — this is a mandatory safety requirement, not optional.

How do I order Upacit XR through Meds For Cancer?

Contact us via WhatsApp (+880 130 449 8958) or email (info@medsforcancer.com) with your physician’s prescription. Our team will verify the prescription, confirm availability and pricing, and arrange international shipping under the Named Patient Program.

🛡 Named Patient Program

Meds For Cancer operates as an NPP facilitator. WHO-GMP certified medicines are made available to patients with a confirmed medical need and valid prescription.

Clinical References